Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7126 to 7140 of 7675 results

  1. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Technology appraisal guidance
    Published
    25 April 2012

  2. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

    Technology appraisal guidance
    Published
    25 April 2012

  3. Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255)

    This guidance has been updated and replaced by NICE technology appraisal guidance 391.

    Technology appraisal guidance
    Published
    11 May 2012

  4. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Technology appraisal guidance
    Published
    27 July 2011

  5. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Technology appraisal guidance
    Published
    27 July 2011

  6. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    24 August 2011

  7. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Technology appraisal guidance
    Published
    24 August 2011

  8. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Technology appraisal guidance
    Published
    30 November 2011

  9. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Technology appraisal guidance
    Published
    19 April 2011

  10. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Technology appraisal guidance
    Published
    27 March 2001

  11. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    27 April 2011

  12. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Technology appraisal guidance
    Published
    27 April 2001

  13. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Technology appraisal guidance
    Published
    13 January 2012

  14. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Technology appraisal guidance
    Published
    25 January 2012

  15. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Technology appraisal guidance
    Published
    26 June 2001